Residual cardiovascular risk beyond LDL-C in ASCVD: Biological drivers, biomarkers, and therapeutic strategies
Acta Pharmaceutica Sinica B · 2026-11
DOI: 10.1016/j.apsb.2026.11.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-11. Verfasst von Ke Gong und 6 weiteren Autor:innen. Die Arbeit nennt 277 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Hubei Province Natural Science Foundation.
Abstract (Originalsprache)
Atherosclerotic cardiovascular disease (ASCVD) remains associated with recurrent ischemic events despite guideline-directed secondary prevention and intensive low-density lipoprotein cholesterol (LDL-C) lowering. Residual cardiovascular risk refers to the risk that persists after guideline-directed secondary prevention has been optimized and encompasses both residual ApoB-containing lipoprotein burden and non-lipid mechanisms. We organize residual risk into five overlapping biological domains: lipoprotein-related risk; inflammatory risk; thrombotic risk; cellular stress, defective clearance, and regulated cell death; and systemic drivers, including gut-derived metabolites, clonal hematopoiesis, and aging. Lipoprotein-related, inflammatory, and thrombotic risk can be assessed using clinically available biomarkers and risk profiles, whereas cellular-stress and systemic mechanisms remain largely investigational. Cardiovascular outcome data support icosapent ethyl, low-dose colchicine, dual-pathway antithrombotic therapy, and further ApoB lowering in selected patients. In contrast, lipoprotein(a)-directed oligonucleotides, apolipoprotein C-III and angiopoietin-like 3 inhibition, interleukin-6 blockade, factor XI/factor XIa inhibition, and interventions targeting cellular stress or defective clearance either remain investigational or have not demonstrated definitive cardiovascular benefit. This pharmacology-oriented review links clinically available biomarkers to residual-risk mechanisms and distinguishes treatments supported by cardiovascular outcome evidence from those that remain investigational.
Förderung
- National Natural Science Foundation of China
- Hubei Province Natural Science Foundation
Zitieren
APA
Gong, K., Tang, J., Berestovskaya, V. S., Heimo, T., Wang, H., Huang, H., & Duan, Y. (2026). Residual cardiovascular risk beyond LDL-C in ASCVD: Biological drivers, biomarkers, and therapeutic strategies. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.11.011
Vancouver
Gong K, Tang J, Berestovskaya VS, Heimo T, Wang H, Huang H, et al. Residual cardiovascular risk beyond LDL-C in ASCVD: Biological drivers, biomarkers, and therapeutic strategies. Acta Pharmaceutica Sinica B. 2026. doi:10.1016/j.apsb.2026.11.011
BibTeX
@article{Gong2026,
author = {Gong, Ke and Tang, Junming and Berestovskaya, Viktoria Stanislavovna and Heimo, Teppo and Wang, Hao and Huang, Hui and Duan, Yajun},
title = {Residual cardiovascular risk beyond LDL-C in ASCVD: Biological drivers, biomarkers, and therapeutic strategies},
journal = {Acta Pharmaceutica Sinica B},
year = {2026},
doi = {10.1016/j.apsb.2026.11.011}
}
EUVIMED